Corium International

What Corium International does

Corium International (legal entity Corium, Inc.) is a U.S.-based pharmaceutical company founded in 1995 and headquartered in Menlo Park, California, focused on central nervous system (CNS) therapeutics. The company historically developed transdermal drug delivery technologies and has concentrated its commercial efforts on AZSTARYS, an FDA-approved ADHD medication, with U.S. commercialization supported by a $235 million term loan facility from Hercules Capital executed in September 2021. Beyond AZSTARYS, Corium is advancing an Alzheimer's disease treatment through its development pipeline, representing its primary pipeline-stage asset.

Corium's product portfolio is anchored on a single approved CNS asset (AZSTARYS) and one pipeline-stage Alzheimer's program. The company executed a SPAC-led transition to public-market status around 2021 under the ticker CORI, and subsequently the security is listed as delisted. Earlier corporate history includes the 2007 acquisition of StrataGent Life Sciences to extend transdermal delivery capabilities, and a series of equity and debt financings between 2007 and 2021 totaling on the order of $448 million (aggregating the disclosed rounds). Leadership is anchored by founder Gary W. Cleary, who serves as President and CTO.

Revenue mechanics are tied to U.S. pharmaceutical product sales of AZSTARYS via direct/field-sales distribution to prescribers and downstream pharmacy channels. Corium has 501-1,000 employees per the firmographics, and the company pursued enterprise field sales as its go-to-market model. No public pricing for AZSTARYS or other terms is disclosed, and no revenue figure is available in the source data. Operating status indicators are mixed: financing through 2021 supports ongoing operations, but the corporate website (coriumgroup.com) currently returns a CloudAccess.net error page rather than active content, and the equity is delisted, suggesting significant operational or market-structure stress following the 2021 transition.

Name

Corium International

Legal name

Corium, Inc.

Website

https://coriumgroup.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Corium International (Corium, Inc.) is a U.S. CNS pharmaceutical company commercializing AZSTARYS, an FDA-approved ADHD medication, in the United States, with an Alzheimer's treatment in its development pipeline.

Ownership category

akta.pro rank

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Technology or R&D, Supply Chain, Personnel

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from commercialization of FDA-approved drugs, specifically AZSTARYS for ADHD treatment. The company is pursuing traditional pharmaceutical commercialization with initial U.S. focus.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Corium International is a pharmaceutical company that develops and commercializes advanced transdermal drug delivery technologies and CNS (central nervous system) therapies. Its primary commercial product is AZSTARYS, an FDA-approved medication for ADHD, while it also advances a development pipeline including an Alzheimer's disease treatment.

Product overview

Corium International is a pharmaceutical company focused on CNS (central nervous system) therapies. The company operates a portfolio that includes AZSTARYS, an FDA-approved ADHD drug that is being commercialized in the U.S. market, alongside a pipeline of CNS treatments including an Alzheimer's disease therapy in development. The product strategy centers on bringing novel CNS medications to market, with initial commercialization efforts concentrated on AZSTARYS.

Differentiator

Problem solved

Functional benefit

Brands

• AZSTARYS: FDA-approved ADHD medication commercialized by Corium.

Products and services

• AZSTARYS
• Alzheimer's Treatment (Pipeline)

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Biogen: Major CNS-focused biotech with leading Alzheimer's programs (e.g., Aduhelm, Leqembi). Relevant comparator for the Alzheimer's development pathway Corium is pursuing.
• Jazz Pharmaceuticals: Larger specialty pharma with a significant CNS franchise including ADHD-adjacent products. Comparable as a CNS-focused commercial-stage specialty pharmaceutical operator, though broader and more diversified than Corium.
• Pfizer: Large incumbent pharma with a major ADHD portfolio (Quillivant, Quillichew) and significant CNS R&D. Overlaps with Corium in ADHD commercialization and CNS pipeline development.
• Teva Pharmaceutical Industries: Global generic and specialty pharma with a leading ADHD franchise (generic Adderall, branded equivalents). Competes directly with AZSTARYS in the U.S. ADHD stimulant market.
• Eli Lilly: Major incumbent pharma with deep CNS/Alzheimer's R&D pipeline and established CNS commercial infrastructure. Relevant peer for the Alzheimer's pipeline opportunity and competitive context.

Direct peers

• Adamas Pharmaceuticals: CNS specialty pharma with neurology products including Parkinson's and dyskinesia treatments. Comparable as a focused CNS specialty commercial-stage company with similar scale and pipeline strategy.
• Supernus Pharmaceuticals: Specialty CNS pharmaceutical company marketing ADHD and neurology products (e.g., Qelbree). Closely comparable to Corium as a CNS-focused specialty pharma with a similar ADHD commercial franchise and CNS pipeline.
• Neos Therapeutics: Specialty pharma focused on ADHD and CNS disorders with extended-release and orally disintegrating formulations. Comparable as an ADHD-focused specialty CNS pharma with formulation-driven differentiation.
• Ironshore Therapeutics: Specialty CNS pharma commercializing ADHD treatments (e.g., Jornay PM). Comparable as a smaller CNS specialty competitor targeting the same ADHD prescriber base as AZSTARYS.
• KemPharm: CNS specialty pharma whose prodrug technology underpins AZSTARYS (licensed to Corium for commercialization). Highly comparable product-technology overlap and ADHD focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/191001304367981
• LinkedInlinkedin.com/company/corium-international

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corium International